![TFD [LOGO].png](https://static.wixstatic.com/media/1c4fd3_548a902f0e634d898458c2078da13fc9~mv2.png/v1/crop/x_67,y_226,w_358,h_43/fill/w_169,h_20,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/TFD%20%5BLOGO%5D.png){kind=small}
![TFD [LOGO] (10).png](https://static.wixstatic.com/media/bea252_c1775b2fb69c4411abe5f0d27e15b130~mv2.png/v1/crop/x_150,y_143,w_1221,h_1193/fill/w_179,h_176,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/TFD%20%5BLOGO%5D%20(10).png)
Novo Nordisk recently announced that it has filed a lawsuit against one compounding pharmacy and refiled a lawsuit against another after discovering impurities in their products claiming to contain the active ingredient for its popular weight-loss drug Wegovy, Patrick Wingrove reported for Reuters.
The Danish drugmaker found impurities in all tested drugs from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida.
The Danish drugmaker found impurities in all tested drugs from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida. Novo had initially sued Brooksville in July and identified a substance called BPC-157 in samples from Wells.
Both cases were filed in Florida on Wednesday.
Brooksville's managing partner, Terry Myers, stated in an email that the company disputes the new allegations and plans to file another motion to dismiss.
In September, the US Food and Drug Administration banned BPC-157 from use in compounded drugs, citing insufficient data on its potential harm to humans and the risk of dangerous immune system reactions.
Novo also noted that the compounded versions of Wegovy from Brooksville were less potent than advertised, with one sample shown to be at least 19% weaker than indicated.
Comments